National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Funding Opportunity Title
Mechanisms Explaining Differences in Depressive and Anxiety Disorders Across Racial/Ethnic Groups (R01)
R01 Research Project Grant
Funding Opportunity Announcement (FOA) Number
Catalog of Federal Domestic Assistance (CFDA) Number(s)
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate innovative research that will expand our current scientific understanding of the social, behavioral, and/or neurobiological mechanisms explaining racial/ethnic differences in the prevalence of depressive and anxiety disorders (major depressive disorder, dysthymia, generalized anxiety disorder, post traumatic stress disorder, social phobia, and panic disorder with and without agoraphobia) and their associated distribution of symptoms (e.g., the number and type of symptoms by racial/ethnic group) in the United States.
September 16, 2011
Open Date (Earliest Submission Date)
October 21, 2011
Letter of Intent Due Date
October 21, 2011
Application Due Date(s)
(Extended to November 28, 2011 per NOT-OD-12-018), Previous Date: November 23, 2011; Original Date November 21, 2011, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)
Scientific Merit Review
Advisory Council Review
Earliest Start Date(s)
(Extended to November 29, 2011 per NOT-OD-12-018), Previous Date: November 24, 2011; Original Date November 22, 2011
Due Dates for E.O. 12372
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
Descriptive epidemiologic studies drawn from representative samples in the United States document substantial variation in the aggregated prevalence of major depressive disorder, dysthymia, generalized anxiety disorder, post traumatic stress disorder, social phobia, and panic disorder with and without agoraphobia (hereafter referred to as depressive and anxiety disorders) by race/ethnicity (1-5). These and other studies have also identified risk and protective factors across racial/ethnic groups. However, little is known about the mechanisms explaining how the identified risk and protective factors confer risk or protection. Mechanisms are defined as the cascades of social, behavioral, and/or neurobiological processes through which risk and protective factors operate to produce depressive and anxiety disorders.
This FOA invites innovative research applications that will move beyond description to explain how risk and protective factors produce racial/ethnic variation in the prevalence of depressive and anxiety disorders and their associated distribution of symptoms in the United States. Applications with a primary focus on describing observed differences in symptoms or associations of risk factors with symptoms, in the absence of attention to the underlying mechanisms responsible, will not be considered responsive to this FOA.
Much of what is known regarding racial/ethnic differences in the observed prevalence of depressive and anxiety disorders derives from descriptive epidemiological studies. According to the NIMH Collaborative Psychiatric Epidemiology Surveys there is wide variation in lifetime and past-year diagnoses of depressive and anxiety disorders across racial/ethnic groups in the United States. For example, Puerto Ricans have the highest documented rates of depressive and anxiety disorders, while Black Americans have the lowest (1-5). These studies have also catalogued some key risk and protective factors across racial/ethnic groups (e.g., specific ethnic subgroup membership, immigration history, gender). For example, in the National Survey of American Life, Black men of Caribbean origin were more likely to have been diagnosed with depressive disorders than Black American men, while Black women of Caribbean origin had lower rates of anxiety disorders than Black American women (3). Similarly, the length of time spent in the United States has been related directly to the prevalence of depressive and anxiety disorders; U.S.-born racial/ethnic subgroups have higher rates of disorder than their foreign-born counterparts (3, 5). Little is known about the processes by which these risk and protective factors produce the observed differences in the prevalence of depressive and anxiety disorders in the United States. Moreover, little is known about variation in symptom patterns across racial/ethnic groups. Examination of symptom distributions in this context may help to untangle the heterogeneity of disorders and move towards dimensions that cut across disorders. Scientific work in these areas was identified as a priority in a May 2010 meeting NIMH convened to address the role of research in reducing mental health disparities (http://www.nimh.nih.gov/research-funding/scientific-meetings/2010/closing-the-gaps-the-role-of-research-in-reducing-mental-health-disparities-in-the-us.shtml).
The goal of this FOA is to stimulate innovative research on the social, behavioral, and/or neurobiological mechanisms that explain how documented risk and protective factors produce racial/ethnic differences in depressive and anxiety disorders and associated symptom distributions. For example:
It is unknown whether racial/ethnic differences in depressive and anxiety disorders may be due in part to neighborhood social dynamics and resources, which have been shown to be protective (e.g., social cohesion, social support, and collective efficacy) or harmful (e.g., segregation). For example, neighborhood social cohesion (6) and collective efficacy (7) have been shown to confer protection against depression. Recent evidence from the United Kingdom indicates a protective effect of neighborhood ethnic density on mental health outcomes, although results vary widely across racial/ethnic groups (8). In the United States, ethnic density overlaps greatly with segregation, creating a tension between protective and harmful neighborhood social dynamics and resources. Importantly, little research has investigated the processes through which protective and harmful neighborhood social dynamics and resources influence individual risk for depressive and anxiety disorders. Moreover, the neighborhood level may be a target for interventions that influence both population- and individual-level mental health outcomes.
It is poorly understood why Blacks have consistently lower rates of depression than Whites, despite a greater cumulative exposure to adversity and stress (9, 10). One hypothesis posits a behavioral mechanism: Blacks engage in coping behaviors that reduce their risk for negative mental health outcomes, at the expense of physical health (11). However, published tests of this hypothesis have generated conflicting results (12-14), indicating the need for further research.
Stress, such as that caused by discrimination (i.e., unfair treatment) and adversity is associated with poor mental health outcomes (15). The brain regulates physiological and behavioral responses to stress through several processes that may provide clues to racial/ethnic variation in prevalence of depressive and anxiety disorders (16). Prolonged exposure to stress can lead to maladaptive activation of stress hormones (e.g., cortisol) and cause wear and tear on the body, (i.e., allostatic load). The amygdala and hippocampus interpret stress, regulate appropriate physiological responses, and are implicated in the pathophysiology of depression and anxiety disorders (16). Still, few studies have linked the impact of discrimination and adversity on allostatic load, brain structure, and/or brain functioning as a potential mechanism for racial/ethnic variation in depressive and anxiety disorders.
To be considered responsive to this FOA, applications must:
Applicants are strongly encouraged to discuss their research plans with the designated NIMH Program Staff prior to submitting an application, and preferably prior to submission of a letter of intent.
Examples of relevant research topics include, but are not limited to:
1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62:593-602.
2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12 month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62:617-27.
3. Williams DR, Gonzalez HM, Neighbors H, Nesse R, Abelson JM, Sweetman J, Jackson JS. Prevalence and distribution of Major Depressive Disorder in African Americans, Caribbean Blacks, and Non-Hispanic Whites: results from the National Survey of American Life. Archives of General Psychiatry 2007;64:305-15.
4. Takeuchi DT, Zane N, Hong S, Chae DH, Gong F, Gee GC, Walton E, Sue S, Alegria M. Immigration-related factors and mental disorder among Asian Americans. American Journal of Public Health 2007;97:84-90.
5. Alegria M, Mulvaney-Day N, Torres M, Polo A, Cao Z, Canino G. Prevalence of psychiatric disorders across Latino subgroups in the United States. American Journal of Public Health 2007;97:68-75.
6. Echeverr a S, Diez-Roux AV, Shea S, Borrell LN, Jackson S. Associations of neighborhood problems and neighborhood social cohesion with mental health and health behaviors: The Multi-Ethnic Study of Atherosclerosis. Health & Place 2008;14:853-65.
7. Ahern J, Galea S. Collective Efficacy and Major Depression in Urban Neighborhoods. American Journal of Epidemiology;173:1453-62.
8. Das-Munshi J, Becares L, Dewey ME, Stansfeld SA, Prince MJ. Understanding the effect of ethnic density on mental health: multi-level investigation of survey data from England. BMJ 2010;341.
9. Williams D, Williams-Morris R. Racism and mental health: the African American experience. Ethnicity & Health 2000;5:243-68.
10. Dohrenwend BP. The role of adversity and stress in psychopathology: some evidence and its implications for theory and research. Journal of Health and Social Behavior 2000;41:1-19.
11. Jackson J, Knight K. Race and self-regulatory behaviors: the role of the stress response and HPA axis in physical and mental health disparities. In: Carstensen L, Schaie K, eds. Social structure, aging, and self-regulation in the elderly. New York: Springer, 2006.
12. Jackson JS, Knight KM, Rafferty JA. Race and unhealthy behaviors: chronic stress, the HPA axis, and physical and mental health disparities over the life course. American Journal of Public Health 2010;100:933-9.
13. Mezuk B, Rafferty JA, Kershaw KN, Hudson D, Abdou CM, Lee H, Eaton WW, Jackson JS. Reconsidering the Role of Social Disadvantage in Physical and Mental Health: Stressful Life Events, Health Behaviors, Race, and Depression. American Journal of Epidemiology 2010;172:1238-49.
14. Keyes KM, Barnes DM, Bates LM. Stress, coping, and depression: testing a new hypothesis in a prospectively studied general population sample of U.S.-born Whites and Blacks. Social Science & Medicine 2011;72:650-9.
15. Williams D, Mohammed S. Discrimination and racial disparities in health: evidence and needed research. Journal of Behavioral Medicine 2009;32:20-47.
16. McEwen BS. Protection and Damage from Acute and Chronic Stress: Allostasis and Allostatic Overload and Relevance to the Pathophysiology of Psychiatric Disorders. Annals of the New York Academy of Sciences 2004;1032:1-7.
Application Types Allowed
Funds Available and Anticipated Number of Awards
The NIMH intends to commit approximately $2,000,000 in FY 2012 to fund up to three grants in response to this FOA. The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Application budgets are not limited, but need to reflect actual needs of the proposed project.
Award Project Period
The total project period for an application submitted in response to this FOA may not exceed 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the following
All Program Director(s)/Principal Investigator(s) (PD(s)/PI(s))
must also work with their institutional officials to register with the eRA
Commons or ensure their existing eRA Commons account is affiliated with the eRA
Commons account of the applicant organization.
All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH support.
For institutions/organizations proposing multiple PD(s)/PI(s), visit the Multiple Program Director(s)/Principal Investigator(s) Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Pamela Y. Collins, M.D., M.P.H.
Office for Research on Disparities and Global Mental Health
National Institute of Mental Health
6001 Executive Boulevard, Room 8130, MSC 9659
Bethesda, MD 20892-9659
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 443-2847
FAX: (301) 443-8552
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies; GWAS) as provided in the SF424 (R&R) Application Guide, with the following modification:
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Foreign (non-US) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD(s)/PI(s) Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the Central Contractor Registration (CCR). Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by the NIMH. Applications that are incomplete and/or nonresponsive will not be reviewed.
In order to expedite review, applicants are requested to notify the NIMH Referral Office by email at NIMHReferral@mail.nih.gov when the application has been submitted. Please include the FOA number and title, PD(s)/PI(s) name, and title of the application.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115,
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field.l How does the application address the social, behavioral, and/or neurobiological processes that produce racial/ethnic differences in the prevalence of depressive and anxiety disorders?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD(s)/PI(s), do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the application use a theoretically-grounded and/or hypothesis-driven approach to advancing understanding of the mechanisms of racial/ethnic differences in the prevalence of depressive and anxiety disorders and the distribution of symptoms?
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed? Does the project provide a strong, hypothesis-driven rationale for examining the specific mechanisms (e.g., social, behavioral, and/or neurobiological) of interest?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Is the data coordination and data sharing plan (e.g., incorporating data dictionaries, current definitions, and careful documentation) likely to be sufficient and effective?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical
merit by (an) appropriate Scientific Review Group(s) convened by the NIMH, in accordance with NIH peer
review policy and procedures, using the stated review
criteria. Review assignments will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Mental Health Council.l The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.